Valuation: Roche Holding AG

Market Cap 289B 353B 306B 262B 491B 33,839B 495B 3,448B 1,329B 17,166B 1,326B 1,297B 54,574B P/E 2026 *
19.6x
P/E 2027 * 17.7x
Enterprise Value 300B 366B 317B 272B 510B 35,112B 514B 3,578B 1,379B 17,812B 1,376B 1,346B 56,629B EV / Sales 2026 *
4.78x
EV / Sales 2027 * 4.47x
Free-Float
88.78%
Yield 2026 *
2.77%
Yield 2027 * 2.84%
Manager TitleAgeSince
Chief Executive Officer 51 2023-03-14
Director of Finance/CFO 59 2011-06-05
Chief Operating Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 68 1995-12-31
Chairman 59 2023-03-14
Director/Board Member 73 2015-03-02
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%+2.01% - - 353B
+2.02%-0.96%+50.69%+92.40% 1,015B
+0.28%-3.24%+49.57%+62.65% 642B
+1.81%+2.07%+19.89%+70.38% 463B
+5.00%+2.21%+36.64%+39.24% 353B
-0.25%-9.20%+15.25%+24.87% 265B
-0.07%+0.93%+3.05%+12.39% 254B
+1.10%-12.75%+38.03%+45.44% 206B
+0.78%-6.21%-19.49%-58.94% 191B
+1.87%-3.04%+27.81%+89.26% 182B
Average +1.05%-3.35%+24.60%+41.97% 396.69B
Weighted average by Cap. +0.96%-2.21%+33.43%+57.25%

Financials

2026 *2027 *
Net sales 62.65B 76.61B 66.38B 56.83B 107B 7,343B 107B 748B 288B 3,725B 288B 281B 11,843B 65.46B 80.05B 69.36B 59.39B 111B 7,673B 112B 782B 301B 3,892B 301B 294B 12,374B
Net income 14.5B 17.73B 15.36B 13.15B 24.67B 1,699B 24.85B 173B 66.71B 862B 66.58B 65.12B 2,740B 16.32B 19.95B 17.29B 14.8B 27.77B 1,913B 27.97B 195B 75.09B 970B 74.95B 73.3B 3,085B
Net Debt 10.87B 13.29B 11.52B 9.86B 18.49B 1,274B 18.63B 130B 50.01B 646B 49.92B 48.81B 2,054B 4.02B 4.91B 4.26B 3.65B 6.84B 471B 6.89B 47.99B 18.49B 239B 18.46B 18.05B 760B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!